{
  "task_id": "e-015",
  "rubric_hash": "8d2b1f0c",
  "scored_at": "2026-01-14T16:34:06.704161",
  "passed": true,
  "total_points": 100,
  "points_earned": 80.75,
  "score_percent": 80.75,
  "llm_gated": false,
  "criteria": [
    {
      "id": "tier_1_targets",
      "passed": true,
      "type": "llm_judge",
      "match_type": "llm_judge",
      "points": 45,
      "points_earned": 38.25,
      "actual": "0.85",
      "details": "Score: 0.85 - Strong selection of 5 well-known, strategically relevant U.S. biotech targets with appropriate market caps ($7-25B range). ITCI, SRPT, ALNY, BMRN, and IONS are all legitimate M&A candidates with commercial assets or late-stage pipelines. Strategic rationales are concise, specific, and demonstrate understanding of acquirer motivations (platform value, commercial infrastructure, rare disease expertise). Market caps appear reasonable for Jan 2026 timeframe. Minor weakness: probabilities stated as ranges rather than point estimates, and source is generic aggregator rather than direct company filings or Bloomberg/FactSet, but overall this is solid professional work that would be usable with light review."
    },
    {
      "id": "tier_2_targets",
      "passed": true,
      "type": "llm_judge",
      "match_type": "llm_judge",
      "points": 35,
      "points_earned": 28.0,
      "actual": "0.80",
      "details": "Score: 0.80 - Appropriate selection of 5 earlier-stage or more speculative targets (ACLX, KRYS, BEAM, RXRX, VKTX) with smaller market caps ($2.7-6.9B). Strategic rationales are thoughtful and differentiate why these are lower probability (platform risk, earlier commercialization, execution dependency). VKTX inclusion is particularly timely given obesity market dynamics. BEAM and RXRX represent emerging modalities (base editing, AI drug discovery) that are plausible but higher risk. Rationales are professional quality. Minor issue: KRYS market cap seems potentially high for a single-product dermatology gene therapy company, and probabilities again are ranges. Overall meets the bar for competent analyst work."
    },
    {
      "id": "source_urls",
      "passed": true,
      "type": "llm_judge",
      "match_type": "llm_judge",
      "points": 10,
      "points_earned": 6.5,
      "actual": "0.65",
      "details": "Score: 0.65 - Provides source URLs (companiesmarketcap.com) with specific pages for each target, which is adequate for market cap verification. However, this is a secondary aggregator rather than primary sources (company filings, SEC documents, or institutional data providers like Bloomberg/FactSet). For a bulge bracket bank, we would expect more rigorous sourcing. The URLs are functional and traceable, making the work usable, but this would need upgrading before client presentation. No sources provided for strategic context or industry trends, only market caps."
    },
    {
      "id": "selection_methodology",
      "passed": true,
      "type": "llm_judge",
      "match_type": "llm_judge",
      "points": 10,
      "points_earned": 8.0,
      "actual": "0.80",
      "details": "Score: 0.80 - Clear, logical explanation of screening criteria: strategic relevance to acquirers, commercial/late-stage presence, feasible market caps, and value unlock potential. The tiering logic (de-risked commercial assets vs platform plays) is sound and reflects real M&A dynamics. Methodology demonstrates understanding of pharma M&A drivers (rare disease, genetic medicines, platform technologies). Could be strengthened with more specifics on screening universe size, quantitative thresholds, or competitive landscape analysis, but the framework is professional and defensible. The reasoning steps provide additional clarity on the process."
    }
  ],
  "judge": "claude-sonnet-4-5-20250929"
}